“Lung cancer has a lot of opportunities for treatment that impacts patients’ quality of life–even in the metastatic setting. If we don’t get the appropriate treatment to the appropriate patient, all these great [molecular] improvements that we’re making will continue to worsen disparities and equity.” - Christopher S. Lathan, MD, MS, MPH
Eliminating Precision Medicine Disparities Overview
[Abstract #123] Identifying barriers to equitable biomarker testing in underserved patients with NSCLC: A mixed-methods study to inform quality improvement opportunities
[Abstract] A United States study focused on patients' understanding of, attitudes towards, and barriers to the use of biomarker testing for NSCLC
Fostering Excellence in Care and Outcomes in Patients with Stage III and IV NSCLC
Molecular Diagnostics in Non-Small Cell Lung Carcinoma
Advanced NSCLC Biomarker Testing (CME/CMLE on-demand course)
Current and Future Trends in NSCLC Biomarker Testing: The American Experience
Biomarkers for Lung Cancer Screening and Detection
[PODCAST] Ep 37: Financial Barriers to Biomarker Testing
Biomarker Testing for Patients With Advanced NSCLC: Real-World Issues and Tough Choices (ASCO Educational Book)
Biomarkers in Lung Cancer (first page preview only)
This podcast is produced as part of the “Eliminating Precision Medicine Disparities” education program. Funding & support provided by Genentech, Janssen, Merck & Co., and Foundation Medicine.
Funding & support provided by Janssen and Pfizer.